c-MET

ADC Related

ADC Antibody ADC Cytotoxin ADC Linker ADCs Drug-Linker Conjugates for ADC
Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD

+MORE

c-MET

c-MET related products

Cat No.	Product Name	CAS No.	Product Description
V119179	3-Fluoro-desmethyl-cabozantinib-C3-O-C3-PEG-acid	2230826-10-3	3-Fluoro-desmethyl-cazozitinib-C3-O-C3-PEG-acid is a target protein ligand-linker conjugate that binds to the c-Met ligand and the PROTAC linker, thereby recruiting E3 ligases.
V0599	AMG-208	1002304-34-8	AMG 208 (AMG-208) is a novel, highly potent and selective triazolopyridazine-based small molecule inhibitor of c-Met with potential antineoplastic activity.
V0600	AMG-458	913376-83-7	AMG 458 (AMG-458) is a novel c-Met inhibitor with potential anticancer activity.
V0602	BMS-754807	1001350-96-4	BMS-754807 (BMS754807) is an orally bioavailable small molecule inhibitor of IGF-1R/InsR (growth factor 1 receptor/insulin receptor family kinases) with potential antineoplastic activity.
V0594	BMS-777607 (BMS-817378; ASLAN-002)	1025720-94-8	BMS-777607 (also called as BMS817378; ASLAN002) is anorally bioavailableinhibitor of the tyrosine kinase c-Metwith potential antitumor activity.
V2760	CEP-40783 (RXDX-106)	1437321-24-8	RXDX-106 (also known as CEP-40783) is an orally bioavailable, nanomolar potent and highly kinase-selective Type II inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively.
V117150	HGF-IN-1	874744-59-9	HGF-IN-1 (the compound on the left in the second row on page 77) is an HGF inhibitor.
V0601	JNJ-38877605	943540-75-8	JNJ-38877605 (JNJ38877605) is an orally bioavailable small-moleculeinhibitor of c-Met with potential antitumor activity.
V4303	MK8033	1001917-37-8	MK-8033 is a novel, potent, selective, ATP competitive small-molecule, dual inhibitor of c-Met/Ron (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
V4304	MK8033 HCL	1283000-43-0	MK-8033 HCl is a novel, potent, selective, ATP competitive small-molecule, dual inhibitor of c-Met/Ron (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
V0597	NVP-BVU972	1185763-69-2	NVP-BVU972 (also names as BVN972; BVN-972) is a novel c-Met inhibitor with potential anticancer activity.
V0603	PF-04217903	956905-27-4	PF-04217903 (PF04217903) is an orally bioavailabe and ATP-competitivesmall-molecule inhibitor of the tyrosine kinase c-Met with potential antitumor activity.
V4454	PF-04217903 mesylate	956906-93-7	PF-04217903 mesylate, the methanesulfonate salt of PF-04217903, is a novel, potent, orally bioavailabe, selective, and ATP-competitive small-molecule tyrosine kinase inhibitor of c-Met with IC50 of 4.8 nM in A549 cell line and with anticancer activity, it is susceptible to oncogenic mutations (with no activity to Y1230C mutant).
V39597	PF-04217903 phenolsulfonate	1159490-85-3	PF-04217903 phenolsulfonate is a novel, highly potent and ATP-competitive inhibitor of c-Met kinase inhibitor with Ki of 4.8 nM for human c-Met and has antiangiogenic properties.
V0591	PHA-665752	477575-56-7	PHA-665752 (PHA665752) is a novel, potent, selective and ATP-competitive small molecule inhibitor of c-Met Kinase with potential antitumor activity.
V7192	RON-IN-1 (SYN1143 )	913376-84-8	SYN1143 is a potent, selective and orally bioactive dual c-Met/RON inhibitor (antagonist) with IC50s of 4 and 9 nM, respectively.
V3475	SAR125844	1116743-46-4	SAR125844 is a novel, potent, highly selective, reversible and ATP-competitive inhibitor ofMET receptor tyrosine kinase (RTK)for intravenous administration, with anIC50of 4.2 nM.
V2988	SCR-1481B1	1174161-86-4	SCR-1481B1 (also known as c-Met inhibitor 2) is a novel potent and selective MET inhibitor.
V0593	SGX-523	1022150-57-7	SGX-523 (SGX 523;SGX523) is a novel, exquisitely selective, and ATP-competitive inhibitor of Hepatocyte growth factor receptor/Met with potential anticancer activity.
V0592	SU11274 (PKI SU11274; PKI SU11274)	658084-23-2	SU11274 (also called PKI-SU11274; PKI-SU-11274) is a novel, potent and selective Met inhibitor with potential antineoplastic activity.